Skip to contentC
CRISPR Therapeutics AG
C
CRSPCRISPR Therapeutics AG Q4 2020 · 10-K
Revenue$370.00K$370.00K−99.5% vs Q4 2019 Net Income-$107.04M-$107.04MN/M vs Q4 2019 EPS Diluted-$1.50-$1.50N/M vs Q4 2019 Operating Income-$107,761,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CRISPR Therapeutics AG · CIK 1674416 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$87,451,000N/M Margins · derivedOperating margin-29124.6%−29138.9 pt vs Q4 2019
Net margin-28929.5%−28969.1 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end